The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:
: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion . The full text and detailed report of this
: £13.0 million (+52.9%), driven by AMR and EMEAI growth. Segment Growth : : £72
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : Co-founder and CEO announced he will step down
: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.
: £12.9 million (+27.4%), supported by synthetic biology.
Co-founder and CEO announced he will step down from his role and the board by the end of 2026.